NEW YORK (Reuters) - A drug from Pfizer Inc delayed progression of advanced kidney cancer by nearly seven months, and by two months longer than a commonly used medicine, in previously treated patients, according to data from a late stage clinical trial.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Pfizer kidney cancer drug effective in phase III study

Newsletter